ORION CORPORATION STOCK EXCHANGE RELEASE 20 October 2010 AT 4.15 PM EET
Orion Corporation has submitted a marketing authorisation application for the intensive care sedative agent dexmedetomidine for the evaluation by the European Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU countries. EMA has announced today that it has validated the centralised marketing authorisation application and initiated the review. The review time for a centralised marketing authorisation application typically exceeds one year.
Timo Lappalainen Reijo Salonen
President and CEO SVP, Research and Development
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Orionintie 1A, FI-02200 Espoo